Biologics Drug Packaging Companies and Developments

Date : 30 October 2025

The global biologics drug packaging market is growing rapidly, with expected revenue reaching hundreds of millions between 2025 and 2034, leading to a shift towards more sustainable transportation. Key market players are focusing on acquisitions and mergers to improve technology for producing biologics drug packaging, which is expected to drive the market growth during this period.

Global Biologics Drug Packaging Market Players

Biologics Drug Packaging Market Companies

Latest Announcements by Biologics Drug Packaging Industry Leaders:

  • In April 2025, According to Novartis CEO Vas Narasimhan, these investments also demonstrate the U.S.'s pro-innovation laws and regulations, which help Novartis company discover the next big medical discoveries for patients. Novartis company are totally confident in 2025 guidance, mid- to long-term sales growth projection, and 2027 core margin quidance of 40%+, and Novartis company is ready for changes in the external environment. [Source: Novartis]

New Advancements in Biologics Drug Packaging Industry

  • In May 2025, The Asahi Kasei boutique commercial-scale biologics contract development and manufacturing organization (CDMO) Bionova Scientific has announced that it has licensed ATM's unique technologies for developing miCHO cell lines and Leap-In Transposase transposon-based gene delivery. A large number of cells with the desired gene insertion, "precise" integration as a single copy into the host cell's genome, and integration into multiple locations within the genome are all made possible by TUM's Leap-In Transposase technology, which can achieve "high levels of gene integration" and lower the risk of gene silencing or other negative effects. Leap-In Transposase technique produces robust, stable, and productive cell lines, even in the stable pool stage, when applied in a cell line development program. [Source: Pharmaceutical Manufaturer]
  • In January 2025, Tanvex BioPharma, Inc. ("Tanvex"), a biologics and biosimilars contract development and manufacturing organization (CDMO), revealed that it has successfully acquired Bora Biologics Co., Ltd. ("Bora Biologics"), a division of Bora Pharmaceuticals. After this transaction, Tanvex will still own and operate its CDMO services under the name Bora Biologics. [Source: Contract Pharma]

Become a valued research partner with us, please feel free to contact us at sales@towardspackaging.com